Business Mizuho Upgrades Belite Bio to “Outperform” with New Target Price Belite Bio (NASDAQ:BLTE) received an upgrade from Mizuho, moving from a “neutral” rating to an “outperform” rating. This change was announced in a research... Editorial4 hours ago